---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022125"
form_type: "8-K"
ticker: "SINT"
cik: "0001269026"
company_name: "Sintx Technologies, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:09:29.969613+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SINTX Q3 2025 net loss narrows to $3.5M; FDA clearance for SINAPTIC wedge system

## Summary
- Net loss of $3.5M ($1.19 per share) vs $6.2M ($6.96 per share) in Q3 2024.
- Revenue of $0.2M, down from $0.8M YoY due to lower grant revenue; operating expenses decreased 51% to $3.4M.
- Cash rose to $6.25M from $3.60M at Dec 2024; raised $4.3M through warrant exercises.
- FDA 510(k) clearance for SINAPTIC Foot & Ankle Osteotomy Wedge System; first commercial revenue from OsseoSculpt recorded.

## SEC filing metadata
- accession: 0001493152-25-022125
- form_type: 8-K
- ticker: SINT
- cik: 0001269026
- company_name: Sintx Technologies, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/0001493152-25-022125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022125
- JSON: https://secwatch.observer/filing/0001493152-25-022125.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022125.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.